liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Cerebrospinal fluid markers of inflammation and brain injury in Lyme neuroborreliosis - a prospective follow-up study
Linköpings universitet, Institutionen för biomedicinska och kliniska vetenskaper, Avdelningen för inflammation och infektion. Linköpings universitet, Medicinska fakulteten. Reg Kalmar Cty, Sweden.
Linköpings universitet, Institutionen för biomedicinska och kliniska vetenskaper, Avdelningen för inflammation och infektion. Linköpings universitet, Medicinska fakulteten. Ryhov Cty Hosp, Sweden.
Univ Gothenburg, Sweden; Sahlgrens Univ Hosp, Sweden; UCL Inst Neurol, England; UK Dementia Res Inst UCL, England; Hong Kong Ctr Neurodegenerat Dis, Peoples R China.
Univ Gothenburg, Sweden; Sahlgrens Univ Hosp, Sweden.
Vise andre og tillknytning
2022 (engelsk)Inngår i: Clinical Chemistry and Laboratory Medicine, ISSN 1434-6621, E-ISSN 1437-4331, Vol. 60, nr 7, s. 1124-1132Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objectives The purpose of this study was to evaluate levels and kinetics of cerebrospinal fluid (CSF) markers of inflammation and brain injury in patients with Lyme neuroborreliosis (LNB). Methods Adult patients with clinically suspected LNB were enrolled, in a prospective clinical study in the South East of Sweden. Patients were classified according to the European Federation of Neurological Societies guidelines. Definite cases of LNB were re-examined one month later including a repeat CSF investigation. Routine laboratory parameters were investigated along with CSF levels of neurodegenerative markers glial fibrillary acidic protein (GFAp), total tau (t-tau) and neurofilament light protein (NFL), as well as neuroinflammatory markers soluble triggering receptor expressed on myeloid cells 2 (sTREM2), YKL-40 and CXCL13. Non-LNB served as controls. An additional comparison group consisted of spinal anesthesia subjects (SAS) without known central nervous system conditions. Results CSF levels of sTREM2 and CXCL13 were elevated in definite LNB patients at diagnosis compared with non-LNB patients (p<0.001) and SAS (p <= 0.01). In addition, CSF levels of sTREM2, YKL-40 and CXCL13 rapidly declined in at follow-up after antibiotic treatment. In contrast, CSF levels of GFAp and t-tau did not differ across LNB groups, and did not change after treatment. Conclusions Although in a limited number of LNB patients, the results indicate a predominance of microglial and neuroinflammatory involvement rather than parenchymal CNS injury in CSF at diagnosis of LNB with a prompt decline after antibiotic treatment. The findings provide pathogenetic insights and may be of value in differential diagnosis of CSF findings.

sted, utgiver, år, opplag, sider
WALTER DE GRUYTER GMBH , 2022. Vol. 60, nr 7, s. 1124-1132
Emneord [en]
biomarkers; brain injury; cerebrospinal fluid; Lyme neuroborreliosis; pathogenesis
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-185010DOI: 10.1515/cclm-2022-0097ISI: 000789622400001PubMedID: 35499913Scopus ID: 2-s2.0-85129829660OAI: oai:DiVA.org:liu-185010DiVA, id: diva2:1658721
Merknad

Funding Agencies|Swedish Society of Medicine; Medical Research Council of South East Sweden (FORSS); Futurum -the Academy of Health and Welfare, Region Jonkoping County; Swedish Research Council [2018-02532, 2017-00915, 2018-02776]; European Research Council [681712]; Swedish State Support for Clinical Research [ALFGBG-720931]; Alzheimer Drug Discovery Foundation (ADDF), USA [201809-2016862, RDAPB-201809-2016615]; AD Strategic Fund and the Alzheimers Association [ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21831377-C]; Olav Thon Foundation; Erling-Persson Family Foundation; Stiftelsen for Gamla Tjanarinnor, Hjarnfonden, Sweden [FO2019-0228]; European Unions Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant [860197]; UK Dementia Research Institute at UCL; Swedish Alzheimer Foundation [AF-742881]; Hjarnfonden, Sweden [FO2017-0243]; Swedish government [ALFGBG-715986]; Swedish County Councils, the ALF-agreement [ALFGBG-715986]; European Union Joint Program for Neurodegenerative Disorders [JPND2019466-236]; National Institute of Health (NIH), USA [1R01AG068398-01]; Alzheimers Association 2021 Zenith Award [ZEN-21-848495]; Medical Inflammation and Infection Centre (MIIC); ALF grants Region Ostergotland [RO-936276]

Tilgjengelig fra: 2022-05-17 Laget: 2022-05-17 Sist oppdatert: 2023-05-04

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Søk i DiVA

Av forfatter/redaktør
Tjernberg, IvarGyllemark, PaulaErnerudh, JanForsberg, PiaSjöwall, JohannaJonsson Henningsson, Anna
Av organisasjonen
I samme tidsskrift
Clinical Chemistry and Laboratory Medicine

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 170 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf